Syros Pharmaceuticals (NASDAQ:SYRS) Raised to “Hold” at ValuEngine

ValuEngine upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a sell rating to a hold rating in a research note published on Wednesday, June 26th, ValuEngine reports.

A number of other research firms have also recently weighed in on SYRS. Roth Capital set a $14.00 price objective on shares of Syros Pharmaceuticals and gave the stock a buy rating in a research report on Friday, March 8th. HC Wainwright reiterated a neutral rating on shares of Syros Pharmaceuticals in a research report on Thursday, May 2nd. Wedbush reiterated an outperform rating on shares of Alphabet in a research report on Thursday, April 25th. BidaskClub upgraded shares of Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, June 20th. Finally, Piper Jaffray Companies set a $44.00 price objective on shares of First Merchants and gave the company a buy rating in a report on Wednesday, April 10th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $16.03.

Shares of SYRS stock traded down $0.02 during trading hours on Wednesday, hitting $7.57. The company’s stock had a trading volume of 98,160 shares, compared to its average volume of 180,646. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.19 and a current ratio of 5.19. The stock has a 50 day simple moving average of $7.15. Syros Pharmaceuticals has a 12-month low of $5.17 and a 12-month high of $13.16. The stock has a market cap of $323.77 million, a PE ratio of -3.94 and a beta of 1.95.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. Syros Pharmaceuticals had a negative net margin of 3,012.04% and a negative return on equity of 74.28%. The firm had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.42 million. Research analysts expect that Syros Pharmaceuticals will post -1.79 EPS for the current year.

In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total transaction of $489,510.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in shares of Syros Pharmaceuticals by 51.4% during the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after purchasing an additional 10,995 shares in the last quarter. BlackRock Inc. boosted its position in shares of Syros Pharmaceuticals by 23.1% during the 4th quarter. BlackRock Inc. now owns 1,986,130 shares of the company’s stock worth $11,063,000 after purchasing an additional 372,462 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Syros Pharmaceuticals by 8.9% during the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after purchasing an additional 6,883 shares in the last quarter. Northern Trust Corp boosted its position in shares of Syros Pharmaceuticals by 0.7% during the 4th quarter. Northern Trust Corp now owns 306,167 shares of the company’s stock worth $1,705,000 after purchasing an additional 2,179 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Syros Pharmaceuticals by 3.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock worth $683,000 after purchasing an additional 3,900 shares in the last quarter. 56.16% of the stock is owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Featured Article: Dividend

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.